Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Eisai-Biogen's Alzheimer's treatment drug receives FDA approval
11:15am, Friday, 07'th Jul 2023
Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the Alzheimer's treatment drug Leqembi. Yahoo Finance Live breaks down the story.
Demand for Biogen's new Alzheimer's drug will surprise to the upside, says Piper Sandler analyst
11:06am, Friday, 07'th Jul 2023
Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like for Biogen's new drug and the serious side effect
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
10:20am, Friday, 07'th Jul 2023
Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Full approval likely means at least $100s millions/annual revenue since Medicare will reimbursement
BIIB Stock Alert: What to Know as FDA Approves Biogen's Alzheimer's Drug
09:57am, Friday, 07'th Jul 2023
Biogen (NASDAQ: BIIB ) stock is in the news Friday after the company got approval from the FDA for its Alzheimer's drug. This covers the traditional approval of LEQEMBI.
5 Things to Know Before Markets Open
07:50am, Friday, 07'th Jul 2023
The government's latest jobs report is expected to show continued strength in the labor market and the FDA gives approval to a new Alzheimer's disease treatment. Here's what investors need to know tod
Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval
07:29am, Friday, 07'th Jul 2023
Biogen Inc.'s stock BIIB, -0.31% rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company's Alzhe
Alzheimer's drug, the first to slow disease progression, gets FDA green light
02:58am, Friday, 07'th Jul 2023
Eisai, a Japanese firm, and American drugs giant Biogen Inc (NASDAQ:BIIB) have received full Food & Drug Administration approval for Leqembi, a groundbreaking drug that curbs Alzheimer's disease progr
FDA Approves Leqembi, Extending Alzheimer's Treatment to More Patients
06:57pm, Thursday, 06'th Jul 2023
Medicare enrollees can get the anti-amyloid treatment as a result of the agency's full approval.
First drug to slow progression of Alzheimer's disease approved in US
06:44pm, Thursday, 06'th Jul 2023
The US Food and Drug Administration (FDA) has fully approved a drug that slows the progression of Alzheimer's disease for the first time.
FDA Grants Full Approval For Alzheimer's Drug, Despite Concerns
05:30pm, Thursday, 06'th Jul 2023
Leqembi costs $26,000 per year before insurance.
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
05:22pm, Thursday, 06'th Jul 2023
'Closing Bell Overtime' breaks latest from the FDA concerning Biogen's Alzheimer's drug.
FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
04:55pm, Thursday, 06'th Jul 2023
The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer's treatment Leqembi, a step that secures Medicare reimbursement for the fi
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
04:44pm, Thursday, 06'th Jul 2023
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map
09:31am, Thursday, 06'th Jul 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
07:30am, Friday, 23'rd Jun 2023
The FDA could soon make a decision on Biogen's Alzheimer's drug, Leqembi. An advisory committee confirmed its clinical benefits, suggesting an approval could be ahead.
